pediatric CNS choriocarcinoma
diseaseOn this page
Also known as Central nervous system choriocarcinomachildhood central nervous system choriocarcinomachildhood choriocarcinoma of the central nervous systemchildhood CNS choriocarcinomachoriocarcinoma of childhood central nervous systemchoriocarcinoma of childhood CNSchoriocarcinoma of paediatric central nervous systemchoriocarcinoma of paediatric CNSchoriocarcinoma of pediatric central nervous systemchoriocarcinoma of pediatric CNSchoriocarcinoma of the central nervous system of childhoodchoriocarcinoma of the childhood central nervous systemchoriocarcinoma of the childhood CNSchoriocarcinoma of the paediatric CNSchoriocarcinoma of the pediatric central nervous systemchoriocarcinoma of the pediatric CNSpaediatric central nervous system choriocarcinomapaediatric choriocarcinoma of the central nervous systempediatric central nervous system choriocarcinomapediatric choriocarcinoma of the central nervous system
Summary
pediatric CNS choriocarcinoma (MONDO:0003953) is a disease and 6 clinical trials. Top therapeutic interventions include leucovorin and pazopanib hydrochloride. A subtype of childhood central nervous system germ cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pediatric CNS choriocarcinoma |
| Mondo ID | MONDO:0003953 |
| DOID | DOID:6639 |
| NCIT | C6206 |
| UMLS | C1377604 |
| MedGen | 234603 |
| GARD | 0023750 |
| Is cancer (heuristic) | no |
Also known as: Central nervous system choriocarcinoma · childhood central nervous system choriocarcinoma · childhood choriocarcinoma of the central nervous system · childhood CNS choriocarcinoma · choriocarcinoma of childhood central nervous system · choriocarcinoma of childhood CNS · choriocarcinoma of paediatric central nervous system · choriocarcinoma of paediatric CNS · choriocarcinoma of pediatric central nervous system · choriocarcinoma of pediatric CNS · choriocarcinoma of the central nervous system of childhood · choriocarcinoma of the childhood central nervous system · choriocarcinoma of the childhood CNS · choriocarcinoma of the paediatric CNS · choriocarcinoma of the pediatric central nervous system · choriocarcinoma of the pediatric CNS · paediatric central nervous system choriocarcinoma · paediatric choriocarcinoma of the central nervous system · pediatric central nervous system choriocarcinoma · pediatric choriocarcinoma of the central nervous system
Disease family
This is a subtype of childhood central nervous system germ cell tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › central nervous system neoplasm › central nervous system germ cell tumor › childhood central nervous system germ cell tumor › pediatric CNS choriocarcinoma
Related subtypes (7): central nervous system endodermal sinus tumor, childhood central nervous system mature teratoma, childhood central nervous system immature teratoma, childhood central nervous system embryonal carcinoma, childhood germ cell brain tumor, childhood central nervous system mixed germ cell tumor, childhood central nervous system germinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 6 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00281944 | PHASE1 | COMPLETED | Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors |
| NCT00387920 | PHASE1 | COMPLETED | Sunitinib in Treating Young Patients With Refractory Solid Tumors |
| NCT00929903 | PHASE1 | COMPLETED | Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment |
| NCT00994500 | PHASE1 | COMPLETED | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma |
| NCT01076530 | PHASE1 | COMPLETED | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors |
| NCT01088763 | PHASE1 | TERMINATED | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LEUCOVORIN | 4 | 1 |
| PAZOPANIB HYDROCHLORIDE | 4 | 1 |
| CHEMBL3109278 | 0 | 1 |
Related Atlas pages
- Drugs: Pazopanib, CHEMBL3109278